ARTL Artelo Biosciences, Inc.
Healthcare$1.71+43.70%ClosedMarket Cap: $4.0M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.13
P/S
0.00
EV/EBITDA
0.53
DCF Value
$-0.04
FCF Yield
-292.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-1602.5%
ROA
-107.6%
ROIC
-157.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-2.7M | $-3.0M | $— | — |
| Q4 null | $0.00 | NaN% | $-2.8M | $-4.2M | $— | — |
| FY null | $0.00 | NaN% | $-11.4M | $-12.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-3.1M | $-3.1M | $— | — |
| Q2 null | $0.00 | NaN% | $-3.1M | $-3.2M | $— | — |
| Q1 null | $0.00 | NaN% | $-2.4M | $-2.4M | $— | — |
| Q4 null | $0.00 | NaN% | $-3.8M | $-3.8M | $— | — |
| FY null | $0.00 | NaN% | $-10.1M | $-9.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-1.2M | $-1.1M | $— | — |
| Q2 null | $0.00 | NaN% | $-2.5M | $-2.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-2.6M | $-2.5M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-3.2M | $-3.1M | $-1.93 | — |